Quick Answer
Century Therapeutics, Inc. reported Cash and Equivalents of $61.85 million for fiscal year 2025.
Century Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $61.85M | +5.8% |
| 2024 | $58.44M | +23.5% |
| 2023 | $47.32M | -43.8% |
| 2022 | $84.27M | +49.3% |
| 2021 | $56.45M | +107.4% |
| 2020 | $27.21M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $55.52M | +5.6% | -2.4% |
| June 30, 2025 | $56.88M | +37.2% | +9.7% |
| March 31, 2025 | $51.87M | +10.8% | -11.3% |
| December 31, 2024 | $58.44M | +23.5% | +11.1% |
| September 30, 2024 | $52.59M | -4.9% | +26.9% |
| June 30, 2024 | $41.46M | -35.7% | -11.4% |
| March 31, 2024 | $46.81M | -46.1% | -1.1% |
| December 31, 2023 | $47.32M | -43.8% | -14.4% |
- Century Therapeutics, Inc. showed an increase of +5.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Century Therapeutics, Inc.’s cash and equivalents has grown by 127.3% (from $27.21 million to $61.85 million).
- The most recent figure is from Century Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: